

Functionalization of OMVs for Biocatalytic Applications

Subjects: **Biochemistry & Molecular Biology**

Contributor: Lita Amalia , Shen-Long Tsai

Outer membrane vesicles (OMVs) are miniature versions of gram-negative bacteria that contain almost the same content as their parent cells, particularly in terms of membrane composition. Using OMVs as biocatalysts is a promising approach due to their potential benefits, including their ability to be handled similarly to bacteria while lacking potentially pathogenic organisms. To employ OMVs as biocatalysts, they must be functionalized with immobilized enzymes to the OMV platform. Various enzyme immobilization techniques are available, including surface display and encapsulation, each with advantages and disadvantages depending on the objectives.

vesicle

functionalization

immobilization



1. Introduction

OMVs were discovered over 50 years ago, and research on them has progressed significantly, particularly in modifying their functionality to expand their application potential. Here focuses on using OMVs as biocatalysts—particularly their functionalization with enzymes and their applications. Functionalizing OMVs for biocatalytic targets involves modified enzymes, with the immobilization of enzymes being the most common and relevant approach. Immobilized enzymes are stronger and more resistant to environmental changes than free enzymes in solution [1] [2]. Additionally, OMVs can transport enzymes to distant targets in a protected state [3]. Therefore, the immobilization of enzymes enables the expansion of OMVs' utility, while enhancing enzymes' activity and stability.

There are several methods of enzyme immobilization, including depositing enzymes on solid matrices, adsorption on porous materials, immobilization via covalent bonds, affinity immobilization, and entrapment or encapsulation [1] [4]. Each of these methods has its own advantages and disadvantages. Enzyme deposition on solid matrices and entrapment are the most commonly applied immobilization methods among these platforms. It is important to note that the chosen immobilization method significantly impacts the modified enzyme's properties. For example, if the goal is to produce an enzyme with a thermally or mechanically stable surface, entrapment using OMVs is the appropriate immobilization method. On the other hand, enzyme deposition on solid matrices, such as enzyme display on the surface of OMVs, may be recommended if the substrate cannot penetrate the trapping matrix due to its limited properties. In relation to the above statements, the method of enzyme immobilization with the OMV platform is also closely related to the prospective applications of OMVs. Here discuss recent research involving techniques pertaining to enzyme entrapment in OMVs and enzyme display on the surface of OMVs to elaborate on the method of enzyme immobilization with the OMV platform (**Table 1**).

Table 1. Methods for immobilizing enzymes using the OMV platform.

Enzyme Immobilization	Superiority	Deficiency	Detail Method/Illustration	Application	Ref.
• Surface display (enzyme display on OMVs surface)					
Fusion with ClyA (and other OMVs' anchoring motifs, such as OmpA)	Numerous outer membrane proteins can serve as anchoring motifs	Limited expression of proteins that are too large to be transported out of the cytoplasm		Degradation of paraoxon and antibiotics	[5]
Bioconjugation with SpyTag/SpyCatcher	Capable of displaying functional proteins that are challenging to export from the cell	SpyTag's and SpyCatcher's covalent bond is irreversible.		Little is known regarding the use of Spy systems to display enzymes on OMVs for biocatalyst purposes	*
Utilization of ice-nucleation protein (INP)	Facilitating assemblies with trivalent scaffolds is highly promising for simultaneously expressing multiple enzymes for cascade reactions	The size of INP is relatively bigger than SpyCatcher.		Enhanced glucose yield from cellulose degradation	[6] [7]
• Encapsulation					
Physical functionalization	Comparatively simple operation	Limited loading efficiency	<ul style="list-style-type: none"> - Incubation - Electroporation - Sonication - Extrusion 	There has been no report on the use of this technique for enzyme entrapment in the OMVs lumen for biocatalytic purposes	

Enzyme Immobilization	Superiority	Deficiency	Detail Method/Illustration	Application	Ref.
Genetic engineering	Improved enzyme stability and offers high loading efficiency	Limited interaction with the surrounding substrate	<ul style="list-style-type: none"> - The use of SpyTag/SpyCatcher 	Decontamination of CWA, including paraoxon	[8] [9] [10]
			<ul style="list-style-type: none"> - Direct binding to Lpp-OmpA 	Hydrolyze DFP and paraoxon	[11]
			<ul style="list-style-type: none"> - Fusion with Tat secretion signal peptide 	GFP entrapment in OMVs lumen (there have been no data for enzyme entrapment utilizes Tat signal for functionalization of OMVs as biocatalysts)	[12]
			<ul style="list-style-type: none"> - Fusion with Sec secretion signal peptide 	Bioconversion of fatty acid	[13]

2. Enzyme Display on OMV Surface

2.1. Fusion with ClyA

The recent prevalence of OMV surface decoration may be traced back to one of the earliest investigations of Kim et al. [5]. That study functionalized the OMV surface using fusion binding with Cytolysin A (ClyA), a pore-forming hemolytic protein (**Table 1**). ClyA, initially identified in the *Escherichia coli* K-12 strain, is known to be one of the periplasmic proteins secreted along with the vesicles from the bacterial cell, suggesting its use in a vesicle transport mechanism in bacteria [14][15][16][17]. The expression of the fusion protein with ClyA outside the cell indicates that this porin can serve as an anchoring motif. While this was one of the pioneer investigations into the

use of OMVs as vaccines, the concept's essence can also be applied to displaying enzymes, thereby broadening the use of OMVs as biocatalysts.

Kim et al. conducted experiments in which they fused several heterologous proteins to the ClyA toxin with N-terminus and C-terminus variations. The proteins β -lactamase (Bla), organophosphorus hydrolase (OPH), and β -galactosidase (LacZ) were coupled with ClyA to produce synthetic OMVs. Before combining ClyA with the enzymes, they fused it with GFP to assess the effect of fusion on the N- and C-termini. The combination of ClyA with GFP, Bla, and OPH, where ClyA was bound to the N-terminus fusion protein, showed a considerable increase in cell-surface and vesicle activity. On the other hand, Bla bound to the N-terminus of ClyA resulted in a significant decrease in activity. Similarly, ClyA bound to the C-terminus of OPH had no measurable effect on OPH activity. Given that the OPH substrate used in the study, paraoxon, is membrane impermeable, OPH bound outside the cell or vesicle was preferred [5]. In line with this hypothesis, Kim et al. also fused LacZ to the C-terminus of the ClyA anchor. Their research suggested that ClyA could serve as an anchoring motif for decorating the surface of OMVs with other proteins. In addition to ClyA, more than 60 membrane proteins have been identified as OMV anchoring proteins, including OmpA [18][19][20][21]. Further investigation of OMVs may uncover additional proteins with essential functions.

2.2. Bioconjugation with SpyTag/SpyCatcher

The SpyTag/SpyCatcher system has emerged as a powerful tool for the covalent bioconjugation of proteins. SpyTag and SpyCatcher are derived from the Cnab2 domain of the fibronectin-binding protein Fbab of *Streptococcus pyogenes*. SpyTag is a small peptide consisting of 13 amino acids, while SpyCatcher is a larger protein fragment containing 116 residues. This system is based on the covalent peptide interactions between SpyTag and SpyCatcher protein pairs, which result in the formation of an irreversible isopeptide bond between lysine and aspartic acid residues. The isopeptide bond formation is spontaneous and occurs within minutes, without the need for specific pH or reaction temperature conditions. In addition, it is compatible with various buffers [22][23][24]. The simplicity and versatility of this system have made it a popular choice for protein ligation studies, including antibody targeting in vaccine development [25][26] and reporter conjugation in biosensor [27] applications.

SpyTag and SpyCatcher can be fused at either the N-terminus or the C-terminus. In addition to directly fusing the functional protein to the anchoring motif, the use of SpyTag or SpyCatcher to fuse with the C-terminus of the outer membrane protein is a way of functionalizing OMVs through surface display. One advantage of using SpyTag or SpyCatcher to fuse with the C-terminus of an outer membrane protein is the ability to display proteins that are challenging to transport out of the cell, such as large proteins or those with limited expression levels in the cytoplasm. To conjugate the fused protein with SpyTag or SpyCatcher, the only requirement is adding the fused protein to the buffer. For instance, the SpyTag/SpyCatcher system was used to display the virulence factor hemoglobin protease (Hbp) on the OMV platform to investigate optimal exposure of multiple antigenic sites to the immune system [25]. The Hbp–SpyTag display was achieved by fusing Hbp to the C-terminus of SpyTag, which enabled the stable attachment of various antigens to Hbp. In this case, SpyTag expressed far from the surface of OMVs provide broad access without steric hindrance for conjugation with its fusion partner, SpyCatcher,

suggesting the potential for more stable attachment of various antigens to Hbp. The SpyTag/SpyCatcher system has also been employed to display the receptor binding domain (RBD) of the SARS-CoV-2 spike protein on the surface of OMVs. That study demonstrated the potential of the SpyTag/SpyCatcher system for displaying complex proteins and suggested its potential use for vaccine development against COVID-19 [26]. Although using the Spy toolbox for functionalizing OMVs as a biocatalyst is uncommon, the concept should inspire future development of OMVs for biocatalytic requirements. The SpyTag/SpyCatcher system offers a simple and efficient method for displaying proteins on the surface of OMVs (Table 1), providing a promising avenue for developing new biocatalysts.

Sometimes the functionalization of OMVs for biocatalyst purposes using the Spy system does not require engineering of the OMV surface. Instead, SpyTag is conjugated to the transmembrane porin protein OmpA at the internal, N-terminus, and C-terminus regions to create an entrapment platform for OMVs. For example, the phosphotriesterase (PTE) enzyme is fused with SpyCatcher, and the sequence leader torA is added to localize PTE-SpyCatcher expression in the periplasm. This allows the enzymes to be encapsulated within the OMVs [8][9]. This research demonstrates that applying the Spy tools is highly adaptable to achieve desired architectural structures and functions, and that it is not restricted to modifying OMV surfaces.

2.3. The Utilization of the Ice-Nucleation Protein

The ice-nucleation protein (INP) is found in bacteria that actively nucleate ice, such as *Pseudomonas syringae* [28], *Pseudomonas fluorescens* [29], and *Erwinia herbicola* [30]. It can speed up the formation of ice crystals in supercooled water [31][32]. This protein comprises over 1200 amino acid residues and consists of three domains: the N-terminus domain, the central cylindrical repeating domain (CRD), and the C-terminus domain. The N-terminus domain is hydrophobic, while the C-terminus domain is hydrophilic. The N-terminus acts as a membrane anchor for the extracellularly expressed C-terminus; however, proteins fused to either or both termini are exposed on the cell surface. The CRD is a catalytic domain that contributes to the formation of ice crystals and is unrelated to anchoring motifs. However, it functions as a distance regulator between heterologous proteins and the cell surface [33][34].

Enzymes can be effectively immobilized on the outer membrane surface using the INP (Table 1). The INP has the ability to display the trivalent scaffold, Scaf3, on the bacteria cell surface by generating the INP-scaf3 fusion by engineering the episomal DNA [6][35]. Park et al. used the INP-scaf3 plasmid, containing three different cohesin domains, to immobilize multiple enzymes on the surface of OMVs simultaneously in the hyper-vesiculating mutant *E. coli* JC8031. This configuration allows the dockerin of each of the three different cellulases to interact with their respective cohesin partners, thereby providing a promising approach for the simultaneous and site-specific expression of multiple enzymes that are useful for cascade reactions [6].

Similarly, Su et al. reported using a different design to engineer the surface of OMVs using the INP. In their study, they fused the OPH enzyme directly to the INP in the pVLT33-INPOPH6 construct to immobilize the enzyme on the surface of OMVs. Additionally, they fused cellulose binding domains (CBD) with the *E. coli* lipidation sequence of

major lipoprotein-outer membrane protein A (Lpp-OmpA) to form the pUCBD plasmid, in which Lpp-OmpA was used as an anchoring motif. This approach allows the two engineered proteins to be expressed outside of the cell, with the CBD providing an advantage in terms of OMV recovery and enabling the synthetic OMV-enzymes to be utilized multiple times [7].

Both studies demonstrated that the INP offers construction flexibility for displaying diverse functional proteins on OMV platforms and facilitates recovery and purification. Thus, this anchoring motif represents a promising tool for future biotechnological applications in enzyme immobilization.

3. OMV-Mediated Encapsulation

Encapsulation does not provide flexible interaction and high mass transfer between proteins and their environment. However, the encapsulation technique offers enzyme protection and increases enzyme stability by shielding enzymes from harsh environments, since the matrices will carry them in the lumen to travel long distances. The use of OMVs as the encapsulation matrices is more commonly applied in biomedicine for loading small molecules, such as pharmaceutical compounds [36][37]. However, this does not preclude its application for the biocatalytic functionalization of OMVs. Huang et al. categorized the functionalization of OMVs into (i) physical or chemical approaches and (ii) genetic engineering [38]. However, researchers do not discuss the functionalization of OMVs through a chemical approach—for instance, the 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride/N-hydroxysuccinimide (EDC/NHS) coupling reaction—as it is not a material encapsulation technique used for functionalized OMVs as biocatalysts.

3.1. Physical Functionalization

Incubation is the simplest way to introduce biomolecules or functional proteins into the lumen of OMVs. However, the loading efficiency is often uncontrolled, requiring large quantities of loading material to be incubated with the growth media. Alternatively, physical functionalization methods, such as electroporation, sonication, and extrusion, have been explored but require greater effort [38][39][40][41]. For instance, electroporation has encapsulated gold nanoparticles (AuNPs) [39]. However, the use of this method for enzyme encapsulation and for utilizing OMVs as biocatalysts has yet to be documented, probably because it is difficult to prepare enzymes in large quantities. Another challenge is that the cargo must be delivered to the lumen while maintaining its enzymatic activity.

3.2. Genetic Engineering Approach

Most OMVs used as biocatalysts are functionalized using genetic engineering approaches, such as the Spy toolbox mentioned earlier (Table 1). The idea of incorporating heterologous proteins into the lumen of OMVs was first explored by Kesty et al., who expressed GFP fused to the Tat signal peptide. This led to the detection of GFP in both the periplasm and OMVs, suggesting that OMVs partially enclose periplasmic contents and transport them outside the cell [12]. Later, the Spy system was developed, which utilized the SpyTag/SpyCatcher pair to bind the PTE enzyme to OmpA on the inner side of the OMV membrane [8][9][10]. In addition to bioconjugation with the Spy

pair bound to the outer membrane protein OmpA, an alternative encapsulation method involves direct binding to the N-terminus of the lipidation sequence (Lpp) (**Table 1**), which has been demonstrated to hold the diisopropyl fluorophosphatase (DFPase) enzyme under the lipid bilayer [11].

Recent studies have shown the potential of signal peptides for localizing fatty acid-converting enzyme expression in the periplasm. While the Tat signal was previously used for this purpose, the enzyme is now secreted into the periplasm via the Sec pathway, guided by the PelB secretion signal peptide (PelBSS) from pectate lyase B of *Erwinia carotovora*. Fatty acid double bond hydratase from *Stenotrophomonas maltophilia* (SmOhyA) and photoactivated fatty acid decarboxylase from *Chlorella variabilis* NC64 A (CvFAP) were fused with PelBSS to allow for periplasmic expression, which was subsequently encased by OMVs [13]. Similarly, in another study, the β -lactamase enzyme encoded by the CMY-10 gene was secreted into the periplasm using PelBSS. Both studies employed a hyper-vesiculating *E. coli* mutant lacking the *tolA* and *tolR* genes [2]. The outer membrane protein serves as an anchoring motif for displaying enzymes or functional proteins extracellularly and as a holding motif for the loading material beneath the lipid bilayer during encapsulation. Moreover, since OMVs contain periplasmic contents, localizing loading material with signal peptides that can penetrate the inner membrane and accumulate in the periplasm significantly aids in immobilizing enzymes by encapsulating them using the OMV platform.

Overall, using signal peptides for enzyme localization and encapsulation within OMVs represents a promising approach for developing novel biocatalysts and drug delivery systems. While more research is needed to optimize the efficiency and specificity of this approach, it has the potential to revolutionize the field of biotechnology and to open new avenues for developing advanced therapeutics.

References

1. Homaei, A.A.; Sariri, R.; Vianello, F.; Stevanato, R. Enzyme immobilization: An update. *J. Chem. Biol.* 2013, 6, 185–205.
2. Woo, J.M.; Kim, M.Y.; Song, J.W.; Baeg, Y.; Jo, H.J.; Cha, S.S.; Park, J.B. Engineering of a bacterial outer membrane vesicle to a nano-scale reactor for the biodegradation of β -lactam antibiotics. *J. Biotechnol.* 2022, 356, 1–7.
3. Kulp, A.; Kuehn, M.J. Biological Functions and biogenesis of secreted bacterial outer membrane vesicles. *Annu. Rev. Microbiol.* 2010, 64, 163–184.
4. Datta, S.; Christena, L.R.; Rajaram, Y.R.S. Enzyme immobilization: An overview on techniques and support materials. *3 Biotech* 2013, 3, 1–9.
5. Kim, J.Y.; Doody, A.M.; Chen, D.J.; Cremona, G.H.; Shuler, M.L.; Putnam, D.; DeLisa, M.P. Engineered Bacterial Outer Membrane Vesicles with Enhanced Functionality. *J. Mol. Biol.* 2008, 380, 51–66.

6. Park, M.; Sun, Q.; Liu, F.; DeLisa, M.P.; Chen, W. Positional assembly of enzymes on bacterial outer membrane vesicles for cascade reactions. *PLoS ONE* 2014, 9, e97103.
7. Su, F.H.; Tabañag, I.D.F.; Wu, C.Y.; Tsai, S.L. Decorating outer membrane vesicles with organophosphorus hydrolase and cellulose binding domain for organophosphate pesticide degradation. *Chem. Eng. J.* 2017, 308, 1–7.
8. Alves, N.J.; Turner, K.B.; Daniele, M.A.; Oh, E.; Medintz, I.L.; Walper, S.A. Bacterial Nanobioreactors-Directing Enzyme Packaging into Bacterial Outer Membrane Vesicles. *ACS Appl. Mater. Interfaces* 2015, 7, 24963–24972.
9. Alves, N.J.; Moore, M.; Johnson, B.J.; Dean, S.N.; Turner, K.B.; Medintz, I.L.; Walper, S.A. Environmental Decontamination of a Chemical Warfare Simulant Utilizing a Membrane Vesicle-Encapsulated Phosphotriesterase. *ACS Appl. Mater. Interfaces* 2018, 10, 15712–15719.
10. Alves, N.J.; Turner, K.B.; Medintz, I.L.; Walper, S.A. Protecting enzymatic function through directed packaging into bacterial outer membrane vesicles. *Sci. Rep.* 2016, 6, 1–10.
11. Thakur, M.; Dean, S.N.; Moore, M.; Spangler, J.R.; Johnson, B.J.; Medintz, I.L.; Walper, S.A. Packaging of Diisopropyl Fluorophosphatase (DFPase) in Bacterial Outer Membrane Vesicles Protects Its Activity at Extreme Temperature. *ACS Biomater. Sci. Eng.* 2022, 8, 493–501.
12. Kesty, N.C.; Kuehn, M.J. Incorporation of Heterologous Outer Membrane and Periplasmic Proteins into *Escherichia coli* Outer Membrane Vesicles. *J. Biol. Chem.* 2004, 279, 2069–2076.
13. Song, J.W.; Baeg, Y.; Jeong, H.Y.; Lee, J.; Oh, D.K.; Hollmann, F.; Park, J.B. Bacterial Outer Membrane Vesicles as Nano-Scale Bioreactors: A Fatty Acid Conversion Case Study. *ChemCatChem* 2021, 13, 4080–4086.
14. Wai, S.N.; Lindmark, B.; Söderblom, T.; Takade, A.; Westermark, M.; Oscarsson, J.; Jass, J.; Richter-Dahlfors, A.; Mizunoe, Y.; Uhlin, B.E. Vesicle-Mediated Export and Assembly of Pore-Forming Oligomers of the Enterobacterial ClyA Cytotoxin. *Cell* 2003, 115, 25–35.
15. Ludwig, A.; Tengel, C.; Bubert, S.B.A.; Benz, R.; Goebel, H.M.-J.W. SlyA, a regulatory protein from *Salmonella typhimurium*, induces a haemolytic and pore-forming protein in *Escherichia coli*. *Mol. Gen. Genet. MGG* 1995, 249, 474–486.
16. Oscarsson, J.; Mizunoe, Y.; Bernt; Uhlin, E.; Haydon, D.J. Induction of haemolytic activity in *Escherichia coli* by the s/yA gene product. *Mol. Microbiol.* 1996, 20, 191–199.
17. Murase, K. Cytolysin A (ClyA): A Bacterial Virulence Factor with Potential Applications in Nanopore Technology, Vaccine Development, and Tumor Therapy. *Toxins* 2022, 14, 78.
18. Li, R.; Liu, Q. Engineered Bacterial Outer Membrane Vesicles as Multifunctional Delivery Platforms. *Front. Mater.* 2020, 7, 10.

19. Molloy, M.P.; Herbert, B.R.; Slade, M.B.; Rabilloud, T.; Nouwens, A.S.; Williams, K.L.; Gooley, A.A. Proteomic analysis of the *Escherichia coli* outer membrane. *Eur. J. Biochem.* 2000, 267, 2871–2881.

20. Lee, E.Y.; Bang, J.Y.; Park, G.W.; Choi, D.S.; Kang, J.S.; Kim, H.J.; Park, K.S.; Lee, J.O.; Kim, Y.K.; Kwon, K.H.; et al. Global proteomic profiling of native outer membrane vesicles derived from *Escherichia coli*. *Proteomics* 2007, 7, 3143–3153.

21. Tokuda, H.; Matsuyama, S.I. Sorting of lipoproteins to the outer membrane in *E. coli*. *Biochim. Biophys. Acta Mol. Cell Res.* 2004, 1693, 5–13.

22. Reddington, S.C.; Howarth, M. Secrets of a covalent interaction for biomaterials and biotechnology: SpyTag and SpyCatcher. *Curr. Opin. Chem. Biol.* 2015, 29, 94–99.

23. Amelung, S.; Nerlich, A.; Rohde, M.; Spellerberg, B.; Cole, J.N.; Nizet, V.; Chhatwal, G.S.; Talay, S.R. The fbab-type fibronectin-binding protein of *streptococcus pyogenes* promotes specific invasion into endothelial cells. *Cell Microbiol.* 2011, 13, 1200–1211.

24. Zakeri, B.; Fierer, J.O.; Celik, E.; Chittcock, E.C.; Schwarz-Linek, U.; Moy, V.T.; Howarth, M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. *Proc. Natl. Acad. Sci. USA* 2012, 109, E690–E697.

25. van den Berg van Saparoea, H.B.; Houben, D.; de Jonge, M.I.; Jong, W.S.P.; Luijink, J. Display of recombinant proteins on bacterial outer membrane vesicles by using protein ligation. *Appl. Environ. Microbiol.* 2018, 84, e02567-17.

26. Jiang, L.; Driedonks, T.A.; Jong, W.S.; Dhakal, S.; Bart van den Berg van Saparoea, H.; Sitaras, I.; Zhou, R.; Caputo, C.; Littlefield, K.; Lowman, M.; et al. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants. *J. Extracell. Vesicles* 2022, 11, e12192.

27. Hatlem, D.; Trunk, T.; Linke, D.; Leo, J.C. Catching a SPY: Using the SpyCatcher-SpyTag and related systems for labeling and localizing bacterial proteins. *Int. J. Mol. Sci.* 2019, 20, 2129.

28. Li, Q.; Yan, Q.; Chen, J.; He, Y.; Wang, J.; Zhang, H.; Yu, Z.; Li, L. Molecular characterization of an ice nucleation protein variant (InaQ) from *Pseudomonas syringae* and the analysis of its transmembrane transport activity in *Escherichia coli*. *Int. J. Biol. Sci.* 2012, 8, 1097–1108.

29. Warren, G.; Corotto, L.; Wolber, P. Conserved repeats in diverged ice nucleation structural genes from two species of *Pseudomonas*. *Nucleic Acids Res.* 1986, 14, 8047–8060.

30. Deininger, C.A.; Mueller, G.M.; Wolber, P.K. Immunological Characterization of Ice Nucleation Proteins from *Pseudomonas syringae*, *Pseudomonas fluorescens*, and *Erwinia herbicola*. *J. Bacteriol.* 1988, 170, 669–675.

31. Lorv, J.S.H.; Rose, D.R.; Glick, B.R. Bacterial Ice Crystal Controlling Proteins. *Scientifica* 2014, 2014, 1–20.
32. Margesin, R.; Schinner, F.; Marx, J.C.; Gerday, C. *Psychrophiles: From Biodiversity to Biotechnology*; Springer: Berlin/Heidelberg, Germany, 2008.
33. Sarhan, M.A.A. Ice nucleation protein as a bacterial surface display protein. *Arch. Biol. Sci.* 2011, 63, 943–948.
34. Li, L.; Kang, D.G.; Cha, H.J. Functional Display of Foreign Protein on Surface of *Escherichia coli* Using N-Terminal Domain of Ice Nucleation Protein. *Biotechnol. Bioeng.* 2004, 85, 214–221.
35. Tsai, S.L.; Oh, J.; Singh, S.; Chen, R.; Chen, W. Functional assembly of minicellulosomes on the *Saccharomyces cerevisiae* cell surface for cellulose hydrolysis and ethanol production. *Appl. Environ. Microbiol.* 2009, 75, 6087–6093.
36. Kuerban, K.; Gao, X.; Zhang, H.; Liu, J.; Dong, M.; Wu, L.; Ye, R.; Feng, M.; Ye, L. Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer. *Acta Pharm. Sin. B* 2020, 10, 1534–1548.
37. Li, Y.; Wu, J.; Qiu, X.; Dong, S.; He, J.; Liu, J.; Xu, W.; Huang, S.; Hu, X.; Xiang, D.X. Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy. *Bioact. Mater.* 2023, 20, 548–560.
38. Huang, Y.; Nieh, M.P.; Chen, W.; Lei, Y. Outer membrane vesicles (OMVs) enabled bio-applications: A critical review. *Biotechnol. Bioeng.* 2022, 119, 34–47.
39. Ayed, Z.; Cuvillier, L.; Dobhal, G.; Goreham, R.V. Electroporation of outer membrane vesicles derived from *Pseudomonas aeruginosa* with gold nanoparticles. *SN Appl. Sci.* 2019, 1, 1600.
40. Somiya, M.; Yoshioka, Y.; Ochiya, T. Drug delivery application of extracellular vesicles; insight into production, drug loading, targeting, and pharmacokinetics. *AIMS Bioeng* 2017, 4, 73–92.
41. Chen, Q.; Bai, H.; Wu, W.; Huang, G.; Li, Y.; Wu, M.; Tang, G.; Ping, Y. Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. *Nano Lett.* 2020, 20, 11–21.

Retrieved from <https://encyclopedia.pub/entry/history/show/110175>